Loading...
XSTOAXIC A
Market cap7mUSD
Dec 23, Last price  
1.33SEK
1D
2.31%
1Q
11.76%
Jan 2017
-74.91%
IPO
-88.16%
Name

aXichem AB (publ)

Chart & Performance

D1W1MN
XSTO:AXIC A chart
P/E
—
P/S
43.46
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
6.83%
Rev. gr., 5y
39.37%
Revenues
2m
-63.87%
000000376,000000344,000343,0001,227,0004,362,0005,007,0001,809,000
Net income
-21m
L+20.57%
-1,048,343-1,714,510-2,373,899-2,357,067-3,483,130-3,656,563-5,628,000-7,423,000-6,072,000-7,375,000-9,927,000-12,678,000-13,515,000-15,093,000-17,260,000-20,811,000
CFO
-16m
L-17.91%
7,417,083-2,998,397-1,131,528-428,503-4,885,777-4,293,957-9,014,000-7,977,000-5,526,000-7,688,000-7,461,000-12,294,000-11,694,000-15,595,000-19,098,000-15,677,000

Profile

aXichem AB, a biotechnology company, engages in the development of natural analogue ingredients in Sweden. It offers aXivite, an natural analogue capsaicin solution for a range of dietary health applications; aXiphen-bio, a bio-repellent for antifouling protection for vessels and marine installations, pest control in agriculture and forestry, and pest control for cable installations in buildings and underground cables; and aXiphen-feed, a solution for enhanced health for chickens, hens, pigs, and piglets. The company was incorporated in 2007 and is based in Malmö, Sweden.
URL
https://www.axichem.se/
IPO date
Jul 10, 2008
Employees
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,809
-63.87%
5,007
14.79%
4,362
255.50%
Cost of revenue
2,019
2,592
11,037
Unusual Expense (Income)
NOPBT
(210)
2,415
(6,675)
NOPBT Margin
48.23%
Operating Taxes
25
25
35
Tax Rate
1.04%
NOPAT
(235)
2,390
(6,710)
Net income
(20,811)
20.57%
(17,260)
14.36%
(15,093)
11.68%
Dividends
Dividend yield
Proceeds from repurchase of equity
28,543
17,735
BB yield
-34.02%
-4.25%
Debt
Debt current
10,268
18,758
Long-term debt
Deferred revenue
Other long-term liabilities
19,556
390
Net debt
5,959
12,209
(9,454)
Cash flow
Cash from operating activities
(15,677)
(19,098)
(15,595)
CAPEX
(2,608)
(4,728)
Cash from investing activities
(5,103)
(2,608)
(4,728)
Cash from financing activities
18,543
18,800
17,735
FCF
(1,216)
(2,816)
(9,831)
Balance
Cash
4,309
6,549
9,454
Long term investments
Excess cash
4,219
6,299
9,236
Stockholders' equity
(125,995)
(13,929)
(11,786)
Invested Capital
184,790
72,989
68,440
ROIC
3.38%
ROCE
4.09%
EV
Common stock shares outstanding
20,924
17,187
16,978
Price
4.01
-71.05%
13.85
-43.70%
24.60
-49.69%
Market cap
83,904
-64.75%
238,035
-43.01%
417,667
-48.42%
EV
89,885
359,749
500,423
EBITDA
3,624
5,926
(4,201)
EV/EBITDA
24.80
60.71
Interest
3,471
2,690
2
Interest/NOPBT
111.39%